The objectives of this prospective observational study were to determine the proportion of patients with traumatic brain injury who received effective anti-seizure prophylaxis. The study was conducted in a tertiary level ICU of a major trauma referral centre between February 2012 and August 2013. A total of 2361 patients were admitted to the ICU in this study period, of whom 125 patients (index) with traumatic head injury were included in this study. The patients had a mean age of 45 years (SD=19), a mean score on the Glasgow Coma Scale of 9 (SD=4), a mean injury severity score of 27 (SD=13) and a mean APACHE III score of 55 (SD=27). Only 13.6 % (17 of 125) of patients were given anti-seizure prophylaxis and phenytoin levels were measured in 9.6% (12 of 125). Although all 12 patients achieved an effective concentration for phenytoin therapy (>40 μmol/l) after the loading dose, no patient had their target concentration consistently maintained in the recommended therapeutic range (40 to 80 μmol/l) throughout the seven-day monitoring period. There was wide fluctuation in phenytoin levels in the patients in this study. Twenty-two (18%) of the index patients had posttraumatic seizures, indicating a high prevalence for this study. Poor compliance with guidelines could possibly explain this phenomenon. Future studies are needed to look at the dosing and monitoring of phenytoin and/or alternative anti-seizure prophylaxis in patients with traumatic brain injury.
Traumatic brain injury (TBI) is the second-largest cause of acquired brain injury in Australia, resulting in significant long-term morbidity and mortality 1 . The Brain Trauma Foundation (BTF) 2 states that post-traumatic seizure (PTS) following TBI is a significant problem and is associated with potential short-and long-term complications. These can either occur immediately (<24 hours), early (less than a week post-injury) or late (greater than a week post-injury). The incidence 2 is between 4% and 25% when patients are followed for 36 months and approximately 50% when patients are followed for 15 years. Most seizures occur within 48 hours. The prevention of early PTS is important because seizures may exacerbate the structural damage to an already-injured brain and may increase the risk of late PTS and chronic epilepsy 3 . TBI can be classified as mild, moderate or severe, based on the patient's level of consciousness as determined by the Glasgow Coma Scale on presentation to the hospital. A score of 13 or higher correlates with mild brain injury; a score of 9 to 12 correlates with moderate injury; and a score of 8 or less indicates severe brain injury 4 .
According to the guidelines issued by the BTF and the American Academy of Neurology 5 for the management of TBI, anti-seizure prophylaxis is only recommended for prevention of early PTS during the first week of injury. Both guidelines suggest giving phenytoin as the anti-seizure prophylaxis post-TBI because of its low side-effect profile compared to phenobarbital, valproate and carbamazepine. However, there is no supportive evidence for the use of prophylaxis beyond seven days to prevent late PTS, and ongoing prophylaxis is not recommended for this reason. Although the BTF reports a lack of data to support a level one recommendation 5, 6 , the American Academy of Neurology guideline provides a level A recommendation for the use of phenytoin in adult patients with severe TBI 7 .
Phenytoin is widely used as an anticonvulsant drug; it has well-established efficacy and the added advantage of being available in both an IV and oral formulation. However, it is a highly protein-bound, hepatically cleared drug and its clearance is subject to patient variations in drug metabolism and protein binding. This can be problematic in critically ill patients who may have an altered pharmacokinetic profile in the context of multi-organ dysfunction and low albumin 8, 9 . It is also a drug with a narrow therapeutic index and requires therapeutic drug monitoring with appropriate dose adjustments to maintain a steady state in the target concentration range 10, 11 . For cost reasons, phenytoin levels in most Australian hospitals are reported as total phenytoin, rather than free phenytoin (the pharmacologically available component), and this further complicates the decisionmaking for dose adjustment because, in patients with low albumin, the reported total phenytoin level may correlate poorly with the available free phenytoin.
Previous studies have shown that poor compliance with BTF guidelines is due to a lack of robust evidence relating to the efficacy of anti-seizure prophylaxis in preventing late-onset PTS or chronic epilepsy 12, 13 , although it has been shown to reduce the incidence of early PTS. One study showed a reduction in early PTS incidence from 14.2% to 3.6% with anti-seizure prophylaxis 14 . The reluctance to use phenytoin for anti-seizure prophylaxis is possibly compounded by the need for therapeutic drug monitoring and the difficulties of interpreting these levels. There have been no studies thus far looking at guideline compliance rate with anti-seizure prophylaxis in a major trauma referral centre in Australasia. Thus the aim of this study was to audit the use of anti-seizure prophylaxis in critically ill patients with traumatic brain injury in an ICU based at a major trauma referral centre in Australia.
Materials and methods

Ethics
Ethical approval for this study was obtained from the Royal Adelaide Hospital Human Research Ethics Committee. Because of the observational design, consent was not required (Approval Number: 110820).
Setting
A prospective single centre study was carried out between February 2012 and August 2013 at a level 3 ICU of a trauma centre with 34 ICU beds in the Royal Adelaide Hospital in South Australia. We prospectively audited consecutive cases of TBI admitted to the ICU over a period of 18 months. The inclusion criteria for this audit were patients over 18 years of age admitted with TBI. Both patients who received phenytoin for early PTS prophylaxis and those who did not were reviewed. Patients with a known seizure disorder and those who were on anti-seizure medication were excluded from this study.
Study design and data collection
We collected patient demographic data (age, gender and diagnosis), laboratory (serum albumin) and CT results from our hospital clinical results system and patients' case notes. APACHE III 15 and injury severity score 16 were calculated within the first 24 hours of the ICU admission for each patient to estimate their hospital mortality.
To ensure that the recorded data was of high fidelity, two teams of investigators collected and reviewed the reports. 
Proportion of patients
For those patients given phenytoin, additional data was collected that included patient weight, phenytoin loading and maintenance doses expressed as mg/kg, and serum concentrations which were audited from the second to the seventh day. Only phenytoin was used as anti-seizure prophylaxis in this audit. All patients commenced on phenytoin received a loading dose of 1 to 1.5 g (range of 10.4 to 18.4 mg/kg) of IV phenytoin, followed by a daily maintenance IV or oral dose of 300 mg (range of 2.5 to 5.5 mg/kg). The first phenytoin concentration on Day 2 was taken at least 20 hours after administration of the loading dose and was followed by daily levels for seven days.
Instruments
The concentrations were assayed by a ADVIA Analyser (Siemens, Bavaria, Germany), which uses an enzymemultiplied immunoassay technique, and reported as total phenytoin concentrations in µmol/l. These levels were then used to calculate a concentration adjusted for serum albumin to more accurately reflect the pharmacologically active, free phenytoin component. This was done using the Sheiner-Tozer equation 17 .
Statistical analysis
Statistical analyses were performed using SAS Version 9.3 (SAS Institute Inc., Cary, NC, USA) by an independent statistician. Variables-age, acute physiology and results of the Chronic Health Evaluation III and Injury Severity Scale-were normally distributed and, therefore, have been described as means.
A P-value <0.05 was considered significant. Fisher's exact test was used to assess the relationship between the absence of anti-seizure prophylaxis and seizures. Seizures were defined as a witnessed generalised tonic clonic seizure.
Results
In total, 125 patients, including 92 males and 33 females, were admitted with TBI to the ICU over a period of 18 months (Figure 1 ). CT brain imaging was performed on all patients with TBI.
The severity of TBI was estimated radiologically using the Marshall CT scoring system 18 (Tables 1 and 2 ).
The average age of patients was 45 (SD=19); 27 patients were over the age of 65. The average admission score on the Glasgow Coma Scale was 9 (SD=4), the average injury severity score was 27 (SD=13) and the average APACHE III score was 55 (SD=27). For the patients on phenytoin, baseline information, including patients' body weight, serum albumin, loading dose (IV) in mg/kg and average maintenance dose (IV or oral) in mg/kgs is presented in Table 3 .
Of the 125 patients admitted with TBI, 48% suffered from severe TBI, 24% with moderate and 28% with mild TBI, respectively (see Table 2 ). Only 13.6% (17 of 125) of the patients admitted with TBI received phenytoin as antiseizure prophylaxis and in patients with severe TBI, only 15% (9 of 60) received anti-seizure prophylaxis. Phenytoin levels were measured for all seven days in 9.6% (12 of 125) of the patients.
Twenty-two (18%) of the 125 patients suffered from PTS within the first seven days. Although two of these patients were in the group treated with phenytoin, the seizures occurred prior to hospital admission and commencement of anti-seizure prophylaxis. No patient had seizures whilst on phenytoin. A total of 104 (87%) patients survived seven days past admission. The relationship between anti-seizure prophylaxis and the frequency of seizures was evaluated using Fisher's exact test (Figure 2 ), which did not reach statistical significance, however, this may reflect a β error.
For all the patients given phenytoin, an IV loading dose of 1 to 1.5 g achieved therapeutic phenytoin levels of >40 µmol/l on Day 2. With a standard oral or IV maintenance dose of 300 mg/day, 83% of these patients were still therapeutic on Day 4 but this fell to 33% by Day 7. Overall, Diffuse injury II Cisterns are present with midline shift 0 to 5 mm and/or lesion densities present.
No high-or mixed-density lesion >25 ml: may include bone fragments and foreign bodies.
Diffuse injury III Cisterns compressed or absent with midline shift 0 to 5 mm, no high-or mixed-density lesion >25 ml.
Diffuse injury IV Midline shift >5 mm, no high-or mixeddensity lesion >25 ml.
Diffuse Injury V (Evacuated mass lesion)
Any lesion surgically evacuated.
Diffuse Injury VI (Nonevacuated mass lesion)
High-or mixed-density lesion >25 ml, not surgically evacuated.
CT=computed tomography. CT=computed tomography, TBI=traumatic brain injury.
there was a wide range of phenytoin levels throughout the seven days of treatment in this group of patients (Table 4 ).
There was a high incidence of non-therapeutic phenytoin levels after Day 1. However, we did not find any association between creatinine clearance as calculated using the Cockcroft-Gault formula (creatinine clearance in patients commenced on phenytoin 199.78 versus creatinine clearance in patients not commenced on phenytoin 183.80, P=0.42).
Discussion
Preventing PTS is greatly important in reducing morbidity and mortality that result from TBI. Currently, there are two established guidelines, one from the BTF (2007) and the other from the American Academy of Neurology (2003), which have reported that phenytoin has been shown to not only reduce the incidence of early PTS 19, 20 but to also lower the mortality rate and cost in comparison with valproate and levetiracetam 6, 7, 21 . Phenytoin is commonly used as a first-line anticonvulsant drug, but monitoring and dose adjustment is required to maintain serum drug levels within the target concentration of 40 to 80 µmol/l to achieve optimal efficacy and safety 22, 23 .
Wide inter-patient and intra-patient variability in serum phenytoin concentrations has been noted in various studies of different population groups and this is particularly so in critically ill patients who may have organ dysfunction, low serum albumin levels and unpredictable drug metabolism 8,9 . In this study, we looked at patients who were admitted to the Royal Adelaide Hospital ICU with TBI. We looked at whether phenytoin was given for seven days, including a day for a loading dose, and noted if the levels remained within the target concentration during the period of treatment.
In our cohort of patients admitted to ICU with TBI, antiseizure prophylaxis was uncommon; only 12 patients of 125 were given phenytoin prophylaxis. There are a number of possible reasons for this result. It may be due to variation in clinical practice and interpretation of imaging studies in our ICU; and the presence or absence of penetrating trauma may have affected the decision-making of our intensive care physicians.
It is also possible that the equivocal evidence for antiseizure prophylaxis in preventing late-onset seizures has been interpreted as a lack of efficacy in preventing early PTS, although this is not the case in the literature, nor was it the case in our audit where 18% (22 of 125) of patients who were not given phenytoin experienced a seizure. The incidence of seizures in our study (18%) may appear higher than previous studies 14 ; however, our study included all types of TBI and not just severe TBI.
There is possibly also a reluctance to use phenytoin, because of its need for monitoring due to its narrow therapeutic index and the difficulty of interpreting those levels. Among the 12 patients given phenytoin in this study, although they achieved therapeutic concentrations after the loading dose, there was wide variation in phenytoin levels over the seven days of therapy. Overall, the reasons for this reluctance to initiate phenytoin prophylaxis remain unclear and are consistent with results of previous studies 22, 23 . In our own unit, this audit has highlighted the need to review our practice of anti-seizure prophylaxis and there has been a subsequent increased uptake of anti-seizure prophylaxis for prevention of early PTS based on recent evidence 24, 25 . 
Limitations and implications
This particular study looked at post-traumatic seizures only and not post-traumatic epilepsy. Based on previously published data, it is apparent that the prevalence of posttraumatic epilepsy is high in severe TBI. Given that 48% of the patients included in this study had severe TBI, of whom only 15% had anti-seizure prophylaxis, the chance of posttraumatic epilepsy is high even though they may not have had post-traumatic seizures.
The other limitation of this study is that we were unable to find any relationship between the dose level and the incidence of seizures, given the very small sample size; also, we may have inadvertently underestimated the incidence of seizures as we included only those with generalised tonic clonic seizures and not those who suffered other types of seizures (e.g. absence seizures as diagnosed by electroencephalography).
Also, this study only reflects the problem (i.e. low rate of compliance with an accepted guideline) and not a solution to the problem, which we intend to further explore in a follow-up study. To overcome the difficulties associated with phenytoin monitoring, our laboratory now reports the total phenytoin levels with a calculated free phenytoin level, which is based on a modification of the Sheiner-Tozer equation 17 .
Conclusion
Despite the recommendation for seizure prophylaxis in the guidelines for management of severe TBI, only a minority of patients received prophylaxis in this level 3 trauma ICU. The prevalence of early post-traumatic seizures was high in this index population and has prompted a need to review our management of these patients. It has also encouraged us to simplify the monitoring of phenytoin by using calculated free phenytoin levels for ease of dose adjustment. In future, as more experience is gained with other agents that have more predictable pharmacokinetic and pharmacodynamic profiles and minimal side-effect profiles such as levetiracetam, we may be able to use an alternative to phenytoin, which may acceptably achieve adequate PTS prophylaxis. 
